New guidelines on eosinophilic esophagitis management were recently developed with the aim of informing treatment decisions among pediatric and adult allergists and gastroenterologists.
Many patients with chronic spontaneous urticaria treated with omalizumab were able to reduce their use of concomitant medications and achieve control of symptoms.
Several treatments were attempted but failed to manage the patient’s conditions, including proton pump inhibitors, topical steroids, a restricted diet, and infliximab (3 doses) for arthritis.
Children who are exposed to ozone and nitrogen dioxide air pollutants at birth and during early life may have an increased risk for incident asthma and eczema compared with children not exposed.
The FDA has accepted for filing the sBLA for omalizumab for the treatment of adults with chronic rhinosinusitis with nasal polyps who have had an inadequate response to intranasal corticosteroids.
